CG Oncology eyes two FDA filings after bladder cancer trial success
The US biotech says its oncolytic virus cretostimogene worked in a Phase 3 study of lower-risk disease, while it enlarges one planned regulatory submission and schedules another.
CG Oncology is lining up two separate US regulatory submissions for cretostimogene grenadenorepvec, its intravesical therapy for bladder cancer, after announcing on 16 November 2026 that the Phase 3 PIVOT-006 study achieved its main goal. The company has not published any commercial projections, and none are assumed here.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): CG Oncology, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.